ORCID: https://orcid.org/0009-0004-4724-3824; Plan, Elodie L. 
ORCID: https://orcid.org/0000-0002-2255-3904; Yousefi, Elham; König, Franz; Posch, Martin 
ORCID: https://orcid.org/0000-0001-8499-8573; Hopfner, Franziska 
ORCID: https://orcid.org/0000-0001-6524-0281; Höglinger, Günter 
ORCID: https://orcid.org/0000-0001-7587-6187 und Karlsson, Mats O. 
ORCID: https://orcid.org/0000-0003-1258-8297
  
(2024):
		Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory.
	
	 In: Movement Disorders, Bd. 39, Nr.  12: S. 2181-2189
	
      
        
          
             [PDF, 1MB]
          
        
      
			  
			  
               
              
  
              Abstract
Background : Progressive supranuclear palsy (PSP) is a neurodegenerative, late-onset disease that is challenging in terms of assessment. The Progressive Supranuclear Palsy Rating Scale (PSPRS), a 28-item clinician-reported scale, is the most established clinical outcome assessment method. Recently, the U.S. Food and Drug Administration (FDA) has proposed a subscale of 10 items as an alternative to full PSPRS. Objectives : To quantitatively evaluate and compare the properties of full PSPRS and the FDA subscale using item response theory. To develop a progression model of the disease and assess relative merits of study designs and analysis options. Methods : Data of 979 patients from four interventional trials and two registries were available for analysis. Our investigation was divided into: (1) estimating informativeness of the 28 items; (2) estimating disease progression; and (3) comparing the scales, trial designs, and analysis options with respect to power to detect a clinically relevant treatment effect. Results : PSPRS item scores had a low pairwise correlation (r = 0.17 ± 0.14) and the items irritability, sleep difficulty, and postural tremor were uncorrelated with the other items. The FDA-selected items displayed higher correlation (r = 0.35 ± 0.14) and were the basis for a longitudinal item response model including disease progression. Trial simulations indicated that identification of a disease-modifying treatment effect required less than half the study size if the analysis was based on longitudinal item information compared with total scores at end-of-treatment. Conclusion : A longitudinal item response model based on the FDA-selected PSPRS items is a promising tool in evaluating treatments for PSP.
| Dokumententyp: | Zeitschriftenartikel | 
|---|---|
| Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy)
		 Medizin > Institut für Schlaganfall- und Demenzforschung (ISD) Medizin > Klinikum der LMU München > Neurologische Klinik und Poliklinik mit Friedrich-Baur-Institut  | 
        
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit | 
| URN: | urn:nbn:de:bvb:19-epub-123130-0 | 
| ISSN: | 0885-3185 | 
| Sprache: | Englisch | 
| Dokumenten ID: | 123130 | 
| Datum der Veröffentlichung auf Open Access LMU: | 13. Dez. 2024 15:16 | 
| Letzte Änderungen: | 07. Jan. 2025 15:28 | 
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 | 
		
	